Prosecution Insights
Last updated: April 19, 2026
Application No. 18/746,530

PULMONARY ARTERIAL COMPLIANCE ENHANCEMENT AND CONTROL DEVICE

Non-Final OA §112
Filed
Jun 18, 2024
Examiner
RABAGLIA, BRIDGET ELIZABETH
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Corvia Medical Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
To Grant
87%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
102 granted / 151 resolved
-2.5% vs TC avg
Strong +19% interview lift
Without
With
+19.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
47 currently pending
Career history
198
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
42.1%
+2.1% vs TC avg
§102
30.3%
-9.7% vs TC avg
§112
20.0%
-20.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 151 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The specification is objected to as failing to provide proper antecedent basis for the claimed subject matter. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o). Correction of the following is required: the limitation “a resiliently collapsible portion configured to transition between an expanded configuration in contact with the shunting device…” as recited in lines 3-4 of section (B) of claim 1. The present disclosure does not provide basis for this language, but only states that “The compliant implant may include a substantially flattened section… which is configured to expand to a rounded shape under a second higher amount of internal blood pressure… The compliant implant may be keyed to the shunting device such that the collapsible portion of the implant substantially faces the shunting device. The shunting device may protrude into the pulmonary artery enough such that when the compliant implant expands due to the systolic pressure wave the expansion around the shunt is limited” (PP [0027]) and “during systole the flattened wall of the compliant implant is configured to expand and substantially fill the space of the pulmonary artery, in the process forcing blood or fluid (saline, radio-opaque contrast, etc.) through the shunting device. During diastole the flattened wall is configured to return to its lower energy shape as depicted in Fig. 3” (PP [0028]). Drawings The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the resiliently collapsible portion having an expanded configuration in contact with the shunting device (claim 1), the secondary anchoring elements (claim 2) comprising barbs or hooks (claim 3) and the proximal and distal anchoring segments comprising a folded up skirting material (claim 17) must be shown or the features canceled from the claims. No new matter should be entered. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 12 is objected to because of the following informality: Claim 12, line 1: “wherein the compliant implant is comprises…” is grammatically incorrect and should be amended to remove the erroneous “is” such that the claim reads “wherein the compliant implant comprises…” instead. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 15-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 14 introduces “at least one tubular extrusion”, but then claim 15 recites “wherein the at least one tubular extrusion and/or a stiffening bar is configured…”. This claim is indefinite because the “and/or” language presents a device which has tubular extrusions or a stiffening bar, opening up the potential for the device to only comprise a stiffening bar when claim 14 explicitly requires at least one tubular extrusion. It is unclear whether at least one tubular extrusion is actually required by claim 15 or not. It is recommended that claim 15 be amended to recite “The system of claim 14, further comprising a stiffening bar configured to adjust a pressure differential required to collapse and expand the compliant implant” instead since claim 14 already requires at least one tubular extrusion, and particularly since the present disclosure does not provide support for the stiffening bar(s) being present without the tubular extrusions (PP [0031]: “The tubular extrusions of Fig. 3 are configured for accepting a number of stiffening bars as necessary. For example, a single stiffening bar may be inserted in the central tubular extrusion for some patients, while other patients may require the use of all three stiffening bars”). Claim 16 inherits the deficiencies of claim 15 but would be allowable if claim 15 were amended as described above. Allowable Subject Matter Claims 1-14 and 17-20 are allowed. The subject matter of the independent claims 1 and 10 filed on 6/18/2024 could either not be found or was not suggested in the prior art of record. With respect to independent claims 1 and 10, the prior art does not disclose or render obvious at the effective filing date of the invention: the system as claimed comprising a shunting device and a compliant implant in combination with the other limitations of the independent claim. The closest prior art is Chang (US PGPub 2026/0007407 A1), which discloses a system for treating heart failure (see Figs. 4A-C), the system comprising a shunting device (402) and a compliant implant (404) configured to transition between an expanded configuration (Fig. 4A) and a collapsed configuration spaced apart from the shunting device (402, Fig. 4B, PP [0065]: “the stent 404 (e.g., at least the midsection 413 of the stent 404) may be at least partially elastic and/or may be configured to elastically recoil back to an original and/or default form. The reduced pressure of the RPA 13 may allow spring-like materials of the stent 404 to push the blood back into the RPA 13 and/or towards the lungs”). However, the filing date of Chang renders it unusable as prior art. Duffy et al. (US PGPub 2013/0204176 A1) discloses a system for treating heart failures comprising a shunting device (900 in Figs. 10A-C) including a resilient valve (920) for controlling the flow of blood between an artery (A) and a vein (V), but fails to disclose or teach a compliant implant as claimed. Furthermore, the prior art of record does not suggest any motivation to modify the Duffy et al. reference to arrive at a compliant implant configured to expand and collapse adjacent a shunt between an artery and a vein. Claims 15-16 are presently rejected under 35 U.S.C. 112(b) but would also be allowable if this rejection were to be obviated via amendment. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bridget E. Rabaglia whose telephone number is (571)272-2908. The examiner can normally be reached Monday - Thursday, 7am - 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jackie Ho can be reached at (571) 272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIDGET E. RABAGLIA/Examiner, Art Unit 3771 /TAN-UYEN T HO/Supervisory Patent Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Jun 18, 2024
Application Filed
Mar 06, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582556
COMPRESSION DEVICE AND METHOD FOR ADHERING COMPRESSION DEVICE
2y 5m to grant Granted Mar 24, 2026
Patent 12582405
CARTRIDGE AND CARTRIDGE SYSTEM
2y 5m to grant Granted Mar 24, 2026
Patent 12582406
CARTRIDGE AND CARTRIDGE SYSTEM
2y 5m to grant Granted Mar 24, 2026
Patent 12575850
ARTICULATING ULTRASONIC SURGICAL INSTRUMENTS AND SYSTEMS
2y 5m to grant Granted Mar 17, 2026
Patent 12576247
INTRODUCER SHEATH SYSTEMS AND METHODS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
87%
With Interview (+19.4%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 151 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month